CD44 and cancer: Thus, selective targeting of CD44v8-10-positive cancer cells by PDT has a greater translational advantage than targeting a constant region of CD44, such as RG735618, which is also expressed ubiquitously on stromal and fibroblast cells, although it is higher in cancer cells.